Novartis | NVS - Ordinary Share Capital



Novartis reported $1.94B in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
AbbVie USD 18M 0 Dec/2024
Amgen USD 538M 33.04B Jun/2025
AstraZeneca USD 1.55B 1.16B Jun/2025
Bausch Health Companies USD 369.75M 10.14B Jun/2025
Biogen USD 146.6M 146.5M Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Canopy Growth CAD 205.15M 8.47B Jun/2025
Corcept Therapeutics USD 105.29M 105.15M Jun/2025
Drreddys Laboratories INR 832.37M 1.63M Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 3M Jun/2025
GlaxoSmithKline GBP 4.15B 2.8B Jun/2025
Glaxosmithkline GBP 4.15B 2.8B Jun/2025
J&J USD 3.12B 0 Mar/2025
Merck USD 1.79B 0 Mar/2025
Novartis USD 793M 0 Dec/2024
Novartis USD 1.94B 1.14B Jun/2025
Pacira USD 44.9M 44.85M Jun/2025
Perrigo USD 137.6M 6.56B Jun/2025
Pfizer USD 5.68B 5.2B Jun/2025
Prestige Brands USD 49.21M 48.65M Jun/2025
Roche Holding CHF 107M 0 Jun/2024
Sanofi 1.22B 36.5M Jun/2025
Sanofi 1.22B 36.5M Jun/2025
Supernus Pharmaceuticals USD 56.12M 130K Jun/2025
Zoetis USD 443.95M 438.95M Jun/2025